Figure 1
Figure 1. BZ has an antithrombotic effect. (A) C57BL/6J mice at age 8 to 12 weeks treated with intraperitoneal BZ injections (0.3 mg/kg) 3 times per week for 2 weeks. Carotid artery thrombosis21 was performed 24 to 30 hours after the last dose of BZ. *P < .05. (B) WBC count, hemoglobin (HB), and platelet (PLT) counts in C57BL/6J mice treated with BZ. (C) C57BL/6J mice treated with BZ as described in (A) were subjected to tail bleeding assay 24 hours after last dose of BZ. (D) The assay used flow cytometry to examine (i) JON/A binding to platelets stimulated with alpha-thrombin, (ii) P-selectin expression of platelets stimulated with alpha-thrombin, (iii) JON/A binding to platelets stimulated with convulxin, and (iv) fibrinogen binding to platelets after stimulation of platelets with adenosine 5′-diphosphate (ADP). The concentration-dependent results are the mean ± standard error of the mean of 5 individual experiments. N.S. no significant difference. *P < .05

BZ has an antithrombotic effect. (A) C57BL/6J mice at age 8 to 12 weeks treated with intraperitoneal BZ injections (0.3 mg/kg) 3 times per week for 2 weeks. Carotid artery thrombosis21  was performed 24 to 30 hours after the last dose of BZ. *P < .05. (B) WBC count, hemoglobin (HB), and platelet (PLT) counts in C57BL/6J mice treated with BZ. (C) C57BL/6J mice treated with BZ as described in (A) were subjected to tail bleeding assay 24 hours after last dose of BZ. (D) The assay used flow cytometry to examine (i) JON/A binding to platelets stimulated with alpha-thrombin, (ii) P-selectin expression of platelets stimulated with alpha-thrombin, (iii) JON/A binding to platelets stimulated with convulxin, and (iv) fibrinogen binding to platelets after stimulation of platelets with adenosine 5′-diphosphate (ADP). The concentration-dependent results are the mean ± standard error of the mean of 5 individual experiments. N.S. no significant difference. *P < .05

Close Modal

or Create an Account

Close Modal
Close Modal